RAMIN MOUSAVI
CEO
CATHWORKS
WHY: Leads Irvine-based developer of the FFRangio system, which provides X-ray imaging of the coronary artery branch and applies machine learning to help doctors identify coronary issues in a noninvasive manner.
IN THE NEWS: Hospital in Lenox Hill, New York, became first institution in the U.S. to perform 1K FFRangio cases.
NOTABLE: Received $75M investment in 2022 from Medtronic, one of the world’s largest medical device makers, marking the biggest investment to date for CathWorks. Agreement provides Medtronic option to buy CathWorks in next two years at a $585M valuation with bonuses that could cause it to soar much higher. Two-time winner of Business Journal awards.
QUOTABLE: If Medtronic were to acquire CathWorks, Mousavi believes it’d be beneficial to keep CathWorks in Orange County. “I think it’d be a great addition to the Medtronic portfolio since they don’t have any cardiovascular presence yet in Orange County.”
